



Emilio Ragosa

Partner

emilio.ragosa@dlapiper.com

New Jersey (Short Hills)

T: +1 973 307 3004

F: +1 973 215 2804

Emilio Ragosa counsels clients on securities offerings, mergers and acquisitions and venture capital transactions.

He also advises on corporate transactions ranging from seed financings, venture financings and private placements to public offerings. Emilio's clients include private and public companies, as well as venture capital firms and underwriters. His experience makes him uniquely capable of advising clients from formation through capital raising until a sale or IPO.

Within the technology industry, Emilio has experience with digital media, financial services technology, e-commerce and healthcare IT. Within the life sciences sector, his experience includes biotechnology, medical devices and specialty pharmaceuticals.

RELATED SERVICES

- Corporate

EXPERIENCE

His experience includes the following representations:

Securities Offerings

- IPOs for several biotech companies, as well as many underwritten follow-on public offerings
- Several biotech companies with their recent PIPE deals, RDOs, ATM and equity-line offerings
- Several multinational pharma companies in connection with their strategic investments in US public companies
- A medical device company in a reverse merger, now commonly referred to as an alternative public offering
- Several funds in PIPEs and RDOs
- Underwriters in a specialty pharma IPO

Mergers and Acquisitions

- A private biotech company in its sale to a large pharma company for up to US\$7 billion
- Combination of a public biotech company client with private biotech and subsequent up-listing on stock exchange
- An Italian specialty pharma company with its acquisition of a US public specialty pharma company
- A public biotech company in its sale to strategic buyer

- A public company in its sale to private equity firm
- A public clinical research organization in several private acquisitions of e-clinical companies
- A public clinical research organization in a public tender offer of a public EDC company
- Multiple private tech and biotech companies in their critical sale transactions

Private Placements

- Private tech and biotech companies with their successful angel and venture financings
- Venture capital firms and other funds with their investments in tech and biotech companies
- Pension funds with investments in private companies

CREDENTIALS

Admissions

- New Jersey
- New York

Prior Experience

While in law school, Emilio gained experience with capital markets working at the New York Stock Exchange. He also interned with Merrill Lynch before attending law school.

Recognitions

- Life Sciences Star: Finance and Transactional, *LMG Life Sciences Guide* (2016, 2017)
- M&A/Corporate and Commercial: Venture Capital and Emerging Companies, *The Legal 500 US* (2016, 2017)
- *Chambers USA: America's Leading Lawyers for Business* (2014–2017, 2019, 2020)
- 40 Under 40, *New Jersey Law Journal* (2010)

Education

- B.S., Rutgers University
- J.D., Rutgers, The State University of New Jersey School of Law, Newark

Memberships

- Capital Markets Editorial Advisory Board, *Law360*, Member (2017)
- NJ Tech Council Board, Member
- New York Venture Capital Association Board, Member
- Order of the Coif, Member
- Phi Beta Kappa, Member

INSIGHTS

Publications

- "SEC Crowdfunding Rule Summary," LawFlash November 6, 2015

Events

Previous

J.P. Morgan Healthcare Conference

13 January 2020

J.P. Morgan Healthcare Conference

BIO's 2019 International Convention

3 - 6 JUN 2019

Philadelphia

- "NYVCA FinTech Rising Summit 2017," October 11, 2017
- "NACD Princeton Chapter Presentation – An Activist Director: Good or Bad for Your Board?," April 21, 2016
- "The Generational Disruption of Corporate America," NACD New Jersey Chapter, October 21, 2015

NEWS

DLA Piper obtains confirmation of plan for Valeritas in first coronavirus-related chapter 11 case

8 June 2020

DLA Piper represented medical device company Valeritas Holdings Inc. in its chapter 11 case in the United States Bankruptcy Court for the District of Delaware.

DLA Piper advises Iovance Biotherapeutics in its US\$604 million common stock offering

4 June 2020

DLA Piper represented Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), in a US\$603.7 million underwritten public offering.
